Lifelink Systems has announced a collaboration with Genentech to provide a suite of conversational technology solutions that will support a broad range of patient experience initiatives at the biotechnology leader. Lifelink Systems will provide Genentech with a platform to power smart digital assistants to help clinical trial participants, patients, caregivers, and providers to receive personalized assistance and support related to clinical research programs and approved therapies.
Lifelink Systems technology has configurations that are designed to support clinical trial programs and medical information desks.
The Lifelink Systems technology will also be used by Genentech to help improve clinical trial diversity and inclusive research efforts. People of color remain vastly underrepresented in clinical research and Genentech is on a mission to change that.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.